Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVITE: In-home Intravesical Therapy for Bladder Cancer
NCT06704191Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bcg vaccine, gemcitabine, docetaxel and mitomycin c in non-muscle-invasive bladder cancer (NMIBC), sponsored by Mayo Clinic. Primary endpoints: Incidence and severity of adverse events at 12 weeks and Feasibility of in-home intravesical therapy at 12 weeks. Started Apr 2025; status: recruiting.
02
Drugs
bcg vaccinegemcitabinedocetaxelmitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06704191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704191.